

NIHR

Nil

The King's Fund

Integrating additional roles into primary care networks

The Additional Roles Reimbursement Scheme (ARRS), introduced in England in 2019, aimed to facilitate the recruitment of 26,000 extra staff to primary care. While extra staff have been employed, they have not been fully integrated into primary care teams. This research focused on four roles — social prescribing link workers; first contact physiotherapists; paramedics and pharmacists — and examined the issues related to the implementation of these roles and the experiences of staff and managers. It found a lack of shared understanding about the purpose of the roles and an overall ambiguity about what multidisciplinary working would mean for GPs. Successful implementation of the scheme requires extensive cultural, organisational and leadership development skills that are not easily accessible to Primary Care Networks.

Systematic search: No

March 2022

<https://www.kingsfund.org.uk/publications/integrating-additional-roles-into-primary-care-networks>

Scottish Medicines Consortium (SMC Advice)

hydrocortisone modified-release (Efmody®)

NOT recommended for use as treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Systematic search: No

March 2022

<https://www.scottishmedicines.org.uk/medicines-advice/hydrocortisone-modified-release-hard-capsules-efmody-full-smc2414/>

sotorasib (Lumykras®)

Accepted for use on an interim basis, subject to ongoing evaluation and future reassessment, as monotherapy for the treatment of adult patients with KRAS G12C-mutated, locally advanced or metastatic, non-small cell lung cancer (NSCLC), who have progressed on, or are intolerant to platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.

Systematic search: No

March 2022

<https://www.scottishmedicines.org.uk/medicines-advice/sotorasib-lumykras-full-smc2443/>

berotralstat (Orladeyo®)

Accepted for restricted use as routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. Restricted to patients who experience ≥ two clinically significant attacks per month.

Systematic search: No

March 2022

<https://www.scottishmedicines.org.uk/medicines-advice/berotralstat-orladeyo-full-smc2405/>

solriamfetol (Sunosi®)

NOT recommended for use to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).

Systematic search: No

March 2022

<https://www.scottishmedicines.org.uk/medicines-advice/solriamfetol-sunosi-osa-full-smc2419/>

dostarlimab (Jemperli®)

Accepted for use, on an interim basis subject to ongoing evaluation and future reassessment, as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regime

Systematic search: No

March 2022

<https://www.scottishmedicines.org.uk/medicines-advice/dostarlimab-jemperli-full-smc2404/>

lorlatinib (Lorviqua®)

Accepted for use as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

Systematic search: No

March 2022

<https://www.scottishmedicines.org.uk/medicines-advice/lorlatinib-lorviqua-abb-smc2415/>

sacituzumab govitecan (Trodelvy®)

Accepted for use for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease.

Systematic search: No

March 2022

<https://www.scottishmedicines.org.uk/medicines-advice/sacituzumab-govitecan-trodelvy-full-smc2446/>

Scottish Government

Suicide ideation - experiences of adversely racialised people: research

Research commissioned by the National Suicide Prevention Leadership Group (NSPLG). Racism, immigration, mistrust of services and community stigma in relation to mental health, suicide ideation and completion are dominant issues. Participants wish to see the implementation of creative, solid, sustainable systemic processes. They want services which understand and respond to their needs as people who have migratory histories and who face racism.

Systematic search: No

March 2022

<https://www.gov.scot/publications/experiences-adversely-racialised-people-scotland-related-suicide-ideation/>

Benzodiazepine use - current trends: evidence review

The review presents an overview of current knowledge of trends around benzodiazepine-related deaths, hospital admissions, police seizures and prescribing practices in Scotland.

Systematic search: No
March 2022

<https://www.gov.scot/publications/evidence-review-current-trends-benzodiazepine-use-scotland/>

Opioid Substitution Therapy (OST) implicated deaths and prescribing: evidence review

This paper summarises current knowledge of trends around methadone and buprenorphine related deaths and changes to prescribing practice in Scotland.

Systematic search: No
March 2022

<https://www.gov.scot/publications/evidence-review-opioid-substitution-therapy-ost-implicated-deaths-prescribing-scotland/>

Primary Care Health Inequalities Short-Life Working Group: report

This report identifies recommendations to maximise primary care's significant potential to tackle health inequalities and inequity across Scotland's communities.

Systematic search: No
March 2022

<https://www.gov.scot/publications/report-primary-care-health-inequalities-short-life-working-group/>

The Chance to Change Scotland report: Report of the Chance 2 Change Expert Reference Group with Lived Experience to the Primary Care Health Inequalities Short Life Working Group This report accompanies the report of the Primary Care Health Inequalities Short Life Working Group (SLWG). It provides lived experience perspectives on health inequalities and inequity, and on how primary care can address these. C2C worked alongside the SLWG as an expert reference group.

Systematic search: No
March 2022

<https://www.gov.scot/publications/chance-change-scotland-report-chance-2-change-expert-reference-group-lived-experience-primary-care-health-inequalities-short-life-working-group/>

Type 2 Diabetes - framework for prevention, early detection and intervention: evaluation

Findings of a qualitative process evaluation of the implementation of the framework for the Prevention, Early Detection and Intervention of Type 2 Diabetes in three early adopter areas (NHS Ayrshire & Arran, NHS Lothian, NHS Fife and NHS Borders working in partnership as the East Region, and NHS Tayside).

Systematic search: No
March 2022

<https://www.gov.scot/publications/evaluation-implementation-framework-prevention-early-detection-intervention-type-2-diabetes/>

SIGN

SIGN 165: Position statement - Use of long-acting injectable buprenorphine for opioid substitution therapy

National position statement containing advice on the use of long-acting injectable buprenorphine for opioid substitution therapy, including statutory advice from the summary of product characteristics and the Scottish Medicines Consortium, consensus statements developed by a multidisciplinary working group of clinical and non-clinical stakeholders using a formal Delphi process, and links to published guidance on long-acting injectable buprenorphine.

Systematic search: No

April 2022

<https://www.sign.ac.uk/our-guidelines/long-acting-buprenorphine/>

NICE – Guidelines

NG191 COVID-19 rapid guideline: managing COVID-19

Existing recommendations on **casirivimab** and **imdevimab** - for people hospitalised because of COVID-19 – were updated on 30 March 2022.

Systematic search: Limited

March 2022

<https://www.nice.org.uk/guidance/ng191>

NG214 Integrated health and social care for people experiencing homelessness

Aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ng214>

NG213 Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

Aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ng213>

NG212 Mental wellbeing at work

Covers how to create the right conditions for mental wellbeing at work. It aims to promote a supportive and inclusive work environment, including training and support for managers and helping people who have or are at risk of poor mental health.

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ng212>

NICE - Technology Appraisal Guidance

TA781 Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ta781>

TA780 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ta780>

TA779 Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ta779>

TA773 Empagliflozin for treating chronic heart failure with reduced ejection fraction

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ta773>

TA775 Dapagliflozin for treating chronic kidney disease

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ta775>

TA776 Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ta776>

TA777 Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ta777>

TA778 Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria

Systematic search: Yes

March 2022

<https://www.nice.org.uk/guidance/ta778>

EPPI Centre

Nil

AHRQ (Agency for Healthcare Research and Quality – USA)

Nil

Health Foundation

A matter of life and death: explaining the wider determinants of health in the UK

This report outlines an evidence-based framing strategy for shifting understanding and building greater support for action to address the wider determinants of health.

Systematic search: No

March 2022

<https://www.health.org.uk/publications/a-matter-of-life-or-death>

Building public understanding of health and health inequalities

There is a mismatch between the public's perceptions of what influences health (namely individual behaviour and access to care) and the clear evidence base demonstrating the significance of wider determinants of health. This paper draws on polling and recent research to explore the reasons behind public attitudes towards health and health inequalities and how public health professionals can use communications techniques to improve public understanding of health inequalities.

Systematic search: No

March 2022

<https://www.health.org.uk/publications/long-reads/building-public-understanding-of-health-and-health-inequalities>

Canadian Agency for drugs and Technologies in Health (CADTH)

Vitamin B12 Testing in People with Suspected Vitamin B12 Deficiency

Findings from 3 diagnostic accuracy studies indicate that individual tests are insufficient to diagnose vitamin B12 deficiency, and a testing strategy that uses homocysteine and methylmalonic acid should be used in individuals suspected or at risk of vitamin B12 deficiency. This is supported by a health technology assessment that concluded that the current evidence does not provide enough information to determine the most appropriate test, or combination of tests to use in these patients. The patient populations varied in the primary studies included in the systematic reviews and in the primary studies identified in this review, which may impact the generalizability of the results.

Reference standards and cut-off values (i.e., thresholds) used to diagnose vitamin B12 deficiency varied in the primary studies. Presentation of units (e.g., pg/mL, pmol/L) also varied, making it difficult to compare results across studies. No studies were identified that evaluated the clinical utility, or cost-effectiveness, of vitamin B12 testing in people with suspected vitamin B12 deficiency.

Systematic search: Limited

March 2022

<https://www.cadth.ca/vitamin-b12-testing-people-suspected-vitamin-b12-deficiency>

Folate Testing in People With Suspected Folate Deficiency

No relevant literature and no evidence-based guidelines were identified regarding the diagnostic test accuracy, clinical utility, and cost-effectiveness of serum folate testing in people with suspected folate deficiency.

Systematic search: Limited

March 2022

<https://www.cadth.ca/folate-testing-people-suspected-folate-deficiency>

Robotic-Assisted Surgical Systems for Knee Arthroplasty

Overall, there was no consensus in the evidence to indicate that robotic-assisted knee arthroplasty provided any superior clinical effectiveness outcomes when compared to conventional techniques. No evidence indicated that robot-assisted knee arthroplasty had worse clinical outcomes than conventional techniques. Evidence did support the association of robotic-assisted knee arthroplasty with decreased length of hospital stay and increased operative time.

Systematic search: Limited

March 2022

<https://www.cadth.ca/robotic-assisted-surgical-systems-knee-arthroplasty>

McGill University Health Centre (Canada)

Nil

Health Information & Quality Authority (Ireland) – Health Technology Assessments

Nil

Campbell Collaboration

Nil

Glasgow Centre for Population Health

Nil

NICE FORWARD PLANNING – Publications due April 2022

Stroke and transient ischaemic attack in over 16s

Clinical Guideline

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults

Clinical Guideline

Adults with complex needs: social work interventions including assessment, care management and support

Social Care

Epilepsies in children, young people and adults

Clinical Guideline

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum chemotherapy

Technology Appraisal

Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

Technology Appraisal

Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies

Technology Appraisal

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma

Technology Appraisal